In Stock Cell Lines
Mus musculus (Mouse)
Breast (mammary gland)
Adherent
The Tnfsf11 Knockout 4T1 Cell Line is a CRISPR/Cas9-edited mouse mammary carcinoma line lacking RANKL (TNFSF11). Derived from the metastatic 4T1 model of triple?negative breast cancer, it enables study of RANKL?dependent bone metastasis and immune modulation. RANKL binding to RANK recruits TRAF6 to activate NF???B and MAPK signaling, leading to osteoclast differentiation and T?cell activation. This cell line is suitable for co?culture osteoclastogenesis assays, in vivo bone metastasis models, and inhibitor screening. Loss of Tnfsf11 mRNA and protein is confirmed by RT?qPCR and Western blot, allowing precise correlation of phenotype with genotype.
CAMK2A Knockout 769-P Polyclonal Cells
Cat. No. ARG35110
MIA3 Knockout NCI-H1975 Polyclonal Cells
Cat. No. ARG16689
MAT2B Knockout HT29 Polyclonal Cells
Cat. No. ARG15037
FST Knockout Lovo Polyclonal Cells
Cat. No. ARG11721
CDNF Knockout Hela Polyclonal Cells
Cat. No. ARG7662
DCAF16 Knockout AGS Polyclonal Cells
Cat. No. ARG2405
The Tnfsf11 Knockout 4T1 Cell Line is a CRISPR/Cas9-edited murine knockout cell line in which the gene encoding RANKL (TNFSF11) has been disrupted in the 4T1 mammary carcinoma background. This loss-of-function model eliminates functional RANKL expression, providing a clean genetic system for dissecting RANKL-dependent signaling events in breast cancer biology.
The parental 4T1 cell line is a widely used BALB/c-derived mammary adenocarcinoma that closely mimics stage IV triple-negative breast cancer in humans. These cells are highly invasive and spontaneously metastasize from the primary tumor to distant sites, including bone, lung, liver, and brain, making them an ideal platform for studying metastatic progression and organ-specific interactions. The 4T1 model retains many features of human disease, including immunosuppressive tumor microenvironment and osteolytic bone lesion formation when cells home to bone.
TNFSF11 (RANKL) is a TNF superfamily cytokine that exists as a transmembrane and soluble protein. Binding to its receptor RANK (TNFRSF11A) on osteoclast precursors recruits TRAF6, which activates the NF-??B pathway via TAK1 and IKK, and MAPK cascades (ERK, JNK, p38). These signals converge on the transcription factors NFATc1 and AP-1 (c-Fos/c-Jun) to drive expression of cathepsin K and TRAP, essential for bone resorption. The pathway is regulated by the decoy receptor osteoprotegerin (TNFRSF11B) and by upstream factors such as PTH, 1,25-dihydroxyvitamin D3, and TNF-??. In breast cancer, tumor-derived RANKL fosters osteoclast-mediated bone destruction and modulates immune cells via dendritic cell survival and T-cell activation. Knocking out Tnfsf11 in 4T1 cells abrogates this signaling, creating a model to separate tumor-intrinsic from host contributions to metastasis.
In the 4T1 model, RANKL secreted by tumor cells drives osteolytic bone metastasis by promoting osteoclastogenesis and the release of matrix-bound growth factors. The Tnfsf11 Knockout 4T1 Cell Line therefore enables dissection of the RANKL-dependent vicious cycle of bone destruction and immune evasion, as RANKL also supports dendritic cell survival and T-cell activity. The syngeneic BALB/c background permits studies in immunocompetent hosts, facilitating analysis of tumor?Cimmune?Cbone interplay without confounding host RANKL.
Key applications include co?culture osteoclast differentiation assays with TRAP staining, in vivo bone metastasis models using intracardiac injection and bioluminescence imaging, and small?molecule screens for RANKL?CRANK inhibitors. Functional knockout is verified by Western blot and RT?qPCR; downstream signaling can be assessed via NF???B luciferase reporter activity or ERK phosphorylation. Additional assays such as ELISA for soluble RANKL, flow cytometry for surface expression, and transwell migration/invasion assays extend the model’s utility. For further details, contact Ascent Research.
